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Abstract 
Psoriasis is associated with an increased risk of cardiovascular disease, a hallmark of which is 
atherosclerosis. The objective of this study was to review the pertinent literature and high-
light pathogenic mechanisms shared between psoriasis and atherosclerosis in an effort to 
advocate early therapeutic or preventive measures. We conducted a review of the current 
literature available from several biomedical search databases focusing on the developmental 
processes common between psoriasis and atherosclerosis. Our results revealed that the 
pathogenic mechanisms shared between the two diseases converged onto “inflammation” 
phenomenon. Within the lymph nodes, antigen-presenting cells activate naive T-cells to in-
crease expression of LFA-1 following which activated T-cells migrate to blood vessel and 
adhere to endothelium. Extravasation occurs mediated by LFA-1 and ICAM-1 (or CD2 and 
LFA-3) and activated T-cells interact with dendritic cells (and macrophages and keratinocytes 
in psoriasis or smooth muscle cells in atherosclerosis). These cells further secrete chemo-
kines and cytokines that contribute to the inflammatory environment, resulting in the for-
mation of psoriatic plaque or atherosclerotic plaque. Additionally, some studies indicated 
clinical improvement in psoriasis condition with treatment of associated hyperlipidemia. In 
conclusion, therapeutic or preventive strategies that both reduce hyperlipidemia and suppress 
inflammation provide potentially useful approaches in the management of both diseases. 
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Introduction 
Psoriasis is a hereditary, chronic im-
mune-mediated inflammatory skin disorder of un-
known etiology. The disease is estimated to affect 
2-3% of the general population worldwide [1]. Indeed, 
psoriasis has a complex genetic predisposition, but its 
development and/or exacerbation appear to involve 
an interaction between multiple genetic and envi-
ronmental risk factors. Hereditary or genetic factors 
play a part in the development of the disease. In some 
patients, family members may also be affected by 
psoriasis.  However, the exact pattern of inheritance 
remains to be clarified. With the advent of recent de-
velopments in understanding the role of inflamma-
tion in the pathogenesis of psoriasis, it is now widely 
believed that psoriasis is not just a skin disease but a 
systemic inflammatory process [2, 3]. On the other 
hand, cardiovascular disease frequently develops in 
individuals with persistent hyperlipidemia. Other risk 
factors such as hypertension, vascular endothelial cell 
dysfunction, oxidative stress, hyperhomocysteinemia, 
diabetes, smoking, high alcohol consumption, obesity, 




visceral tissue and their adipokines, can also be in-
volved [4-6]. These factors contribute to the formation 
of atherosclerosis which is a hallmark of cardiovas-
cular disease and in which inflammation plays a ma-
jor role [7, 8]. In addition, the same factors are also 
implicated in psoriasis patients [9, 10].Cardiovascular 
disease is an important cause of morbidity and mor-
tality in patients with psoriasis. The risk factors for 
cardiovascular disease as well as myocardial infarc-
tion occur with higher incidence in patients with pso-
riasis and appear to be highest for those with more 
severe disease [11]. Moreover, psoriasis was sug-
gested as an independent risk factor for cardiovascu-
lar disease [12], however some recent studies have not 
supported this notion [13-15], therefore this issue re-
mains to be controversial. Here, we review the perti-
nent literature to highlight pathogenic mechanisms 
shared between psoriasis and atherosclerosis in an 
effort to advocate early therapeutic or preventive 
measures. 
Review of the Literature 
We conducted a comprehensive search of the 
current literature on psoriasis and cardiovascular 
disease. The search method and data retrieval was 
mainly the same as reported previously [16]. Briefly, 
the biomedical search databases of PubMed 
(http://www.ncbi.nml.nih.gov/sites/entrez), 
EMBASE (http://embase.com), SCOPUS 
(http://www.scopus.com/home.url) and Google 
Scholar (http://scholar.google.com) were searched by 
entering the terms ‘psoriasis’, ‘cardiovascular dis-
ease’, or ‘atherosclerosis’ individually or in combina-
tions. We also carefully checked the reference list of 
each publication to retrieve additional citations. Data 
were extracted from full texts and/or abstracts. We 
collected data focusing on the pathogenic mechanisms 
of psoriasis and atherosclerosis which is a principal 
cause of cardiovascular disease. Further information 
of interest was also retrieved and included in our 
discretion. 
Results and Discussion 
Several lines of evidence indicated that psoriasis 
is associated with enhanced atherosclerosis and risk 
of cardiovascular disease, and inflammation is a pi-
votal link between psoriasis and atherosclerosis [17, 
18]. In fact, atherosclerosis has a number of common 
pathogenic features with psoriasis. For example, im-
munological activities and pro-inflammatory cyto-
kines play a prominent role in both diseases. In addi-
tion, both conditions share T-helper 1 (Th1) cell me-
diated immune compromise [19-21] and same pattern 
of T cell activation and expression of adhesion mole-
cules [22-24]. It has been shown that CD4+ T cells are 
necessary for inducing and maintaining psoriasis. It is 
also envisaged that CD8+ T-cells are involved in the 
control of the Th1 polarization that is observed in 
psoriasis lesions, and that fluctuations in the severity 
of psoriasis, and even the spontaneous remissions that 
are common in guttate psoriasis, can be explained by 
changes in the balance between CD4+ and CD8+ ef-
fector and regulatory cell subsets [20]. Although the 
mechanisms underlying the association between pso-
riasis and cardiovascular disease still remains poorly 
understood, it appears that inflammation which plays 
a principal role in both diseases provides a common 
pathogenic ground between the two conditions. 
Intercellular adhesion molecules (ICAMs) and 
vascular cell adhesion molecules (VCAM-1), as well 
as some of the integrins, induce firm adhesion of in-
flammatory cells at the vascular surface, whereas 
platelet endothelial cellular adhesion molecules 
(PECAM-1) are involved in extravasation of cells from 
the blood compartment into the vessel and underly-
ing tissue. Also, inflammatory cells roll along the 
blood vessel wall by the interaction between selectins 
(E and P-selectin) expressed by endothelial cells and 
selectin ligands expressed by inflammatory cells [25]. 
Several lines of evidence support a crucial role of ad-
hesion molecules in the development of atherosclero-
sis and plaque instability [24]. Expression of VCAM-1, 
ICAM-1 and L-selectin has been consistently observed 
in atherosclerotic plaques. There is accumulating 
evidence from prospective studies for a predictive 
role of elevated circulating levels of sICAM-1 in in-
itially healthy people, and of sVCAM-1 in patients at 
high risk or with overt cardiovascular disease. Like-
wise, it has been implied that several adhesion mole-
cules including ICAM-1 and VCAM-1 are upregu-
lated in psoriasis [26, 27], implicating their involve-
ment in the pathogenesis of psoriasis.  
Histologically, psoriasis and atherosclerosis 
show common features of infiltrating T-cells, mono-
cytes/macrophages, neutrophils, dendritic cells (DCs) 
and mast cells [28, 29]. The cytokine network in pso-
riasis and atherosclerosis is mainly characterized by 
Th1 type cytokines such as IFNγ, IL-2 and TNFα [20, 
22, 30]. In these lesions, the major cytokine producers 
are dendritic cells, CD4+ and CD8+ T-cells as well as 
keratinocytes. IFNγ and TNFα induce keratinocytes to 
produce IL-6, IL-7, IL-8, IL-12, IL-15, IL 18 and TNFα 
in addition to several other cytokines, chemokines 
and growth factors. IFNγ is an important mediator of 
inflammation in both psoriasis and atherosclerosis 
and can stimulate the expression of MHC class II 
molecules and ICAM-1 [31, 32]. IFNγ is elevated in the 




[33, 34] and may modify the keratinocyte biology by 
increasing keratinocyte proliferation and causing de-
fective cornification leading to typical psoriatic lesion 
[35]. Recent data also show that IFN-γ may be an es-
sential component for growth stimulation of psoriatic 
keratinocyte stem cells, but it requires the presence of 
other growth factors as well [36]. TNFα activates and 
increases keratinocyte proliferation. TNFα also sti-
mulates T-cell and macrophage cytokine and chemo-
kine productions, and the expression of adhesion 
molecules on vascular endothelial cells [28-30]. IL-8 is 
a chemokine with main roles of neutrophil chemo-
taxis and stimulation of the activity of granulocytes in 
the inflammation process of psoriasis and atheroscle-
rosis. In psoriasis, IL-8 from keratinocytes produces a 
chemotactic gradient for the migration of neutrophils 
into the epidermis [37] Furthermore, IL-8, IL-1 and 
TNF-α influence the adhesive properties of neutro-
phils due to an increase in the expression of surface 
adhesive molecules, thus improving the inter-cellular 
interactions with the endothelial cells, which in turn 
contributes to an increase in the passing of the neu-
trophils through the walls of the vessels. Therefore, 
IL-8 contributes to intensification of the reaction and 
to activation of the neutrophils in both conditions. 
IL-18 induces dendritic cells synergistically with 
IL-12, to increase the production of IFNγ. IL-7 and 
IL-15 have been reported to be important for the pro-
liferation and homeostatic maintenance of the CD8+ 
T-cells [30]. IL-6 is produced by endothelial cells, DCs, 
and Th17 cells in lesional psoriatic skin and is en-
countered by trafficking T lymphocytes enabling 
them to escape from regulatory T cell suppression and 
Th17 participation in inflammation [38]. IL-6 mediates 
T cell activation and stimulates proliferation of kera-
tinocytes [39], but also mediates the acute phase re-
sponse. Indeed, C-reactive protein (CRP), a positive 
acute phase protein, is released in response to in-
creased levels of cytokines, such as IL-6 and TNF-α, 
and patients with elevated levels of CRP seem to ex-
hibit an increased risk for adverse cardiovascular 
outcome [40]. Furthermore, the levels of IL-6 and CRP 
have been reported to be raised in psoriatic patients 
and seem to correlate with psoriasis severity [41, 42].  
Angiogenesis is a recognized feature common to 
psoriasis and atherosclerosis and vascular endothelial 
growth factor (VEGF) is a potent pro-angiogenic fac-
tor which has been reported to be upregulated in both 
conditions [43-45], thus may be a link between the two 
conditions. VEGF is also produced by human kerati-
nocytes in response to stimulation with cytokines in-
volved in psoriasis pathogenesis [43]. Also, 
pro-angiogenic cytokines such as TNFα, IL-8 and 
IL-17 which stimulate angiogenesis are involved in 
psoriasis and atherosclerosis development.  
Presently, psoriasis is considered a Th1/Th17 
involved inflammatory disease in which the kerati-
nocytes are activated mainly by mediators produced 
by Th1 cells, but over time the mediators of Th17 cells 
appear to become increasingly important [46]. Like-
wise, Th17 cell response seems to have an important 
role in several cardiovascular diseases [47]. The per-
sistent Th17 activation in psoriatic skin is characte-
rized by infiltration of IL-23-producing DCs and Th17 
cells as well as epidermal overexpression of Th17 
chemokines. IL-17 cells mediate IL-12 and IL-23 which 
have an important role in the pathogenesis of psoria-
sis [48]. Also, the circulating IL-12 is thought to be the 
link between inflammation and Th1-type cytokine 
production in coronary atherosclerosis [32].  
Finally, IL-17 which is produced by activated 
CD4+ T-cells acts synergistically to elicit further pro-
duction of pro-inflammatory cytokines by the kerati-
nocytes. In this fashion, the cytokine network in pso-
riasis can become a self-sustaining process. Thus, the 
production of pro-inflammatory cytokines together 
with the activation of inflammatory cells could con-
tribute to the development of both psoriatic and 
atherosclerotic lesions. 
In brief, the pathogenic mechanisms shared be-
tween psoriasis and cardiovascular disease i.e. athe-
rosclerosis may be explained stepwise as depicted in 
Figure 1 [49]: 1. Within the lymph node, anti-
gen-presenting cells (APCs) activate naive T-cells to 
increase expression of leukocyte-function-associated 
antigen-1 (LFA-1); 2. Activated T-cells migrate to 
blood vessel; 3. Activated T-cells adhere to endothe-
lium (plus macrophages in atherosclerosis); 4. Extra-
vasation occurs mediated by LFA-1 and intercellular 
adhesion molecule-1 (ICAM-1); 5. Activated T-cell 
interacts with dendritic cells (plus macrophages and 
keratinocytes in psoriasis but smooth muscle cells in 
atherosclerosis); 6. Re-activated T-cells and macro-
phages secrete chemokines and cytokines that con-
tribute to the inflammatory environment, resulting in 
the formation of psoriatic plaque or atherosclerotic 
plaque. In addition to the critical role of interaction 
between LFA-1 and its ligand, ICAM-1, the interac-
tion of CD2 and its ligand, LFA-3 is also important in 
facilitation of antigen-recognition in the molecular 
pathways of lymphocyte adhesion [50]. 





Figure 1. Schematic representation of stepwise developmental process shared between psoriatic and atherosclerotic 
lesions. In the lymph node, antigen-presenting cells (APCs) activate naive T-cells to increase expression of leuko-
cyte-function-associated antigen-1 (LFA-1). Activated T-cells migrate to blood vessel and adhere to endothelium (and 
macrophages in case of atherosclerosis). After extravasation mediated by LFA-1 and intercellular adhesion molecule-1 
(ICAM-1) or CD2 and LFA-3, they interact with dendritic cells and macrophages and keratinocytes in psoriasis but smooth 
muscle cells in atherosclerosis. These re-activated T-cells and macrophages secrete chemokines and cytokines that con-
tribute to the inflammatory environment, resulting in the formation of psoriatic plaque or atherosclerotic plaque.  
 
It is noteworthy to elaborate on some studies 
that have indicated clinical improvement in psoriasis 
condition with treatment of associated hyperlipide-
mia.  A pilot study evaluated the effectiveness of 
simvastatin which is a cholesterol lowering statin on 
serum lipoprotein levels and dermatitis in patients 
with severe psoriasis [51]. The authors found elevated 
high-density lipoprotein cholesterol levels and dimi-
nished PASI during the therapy. It was concluded that 
statins can correct lipid metabolism and reduce cuta-
neous lesion in psoriasis. Also, Wolkenstein P, et al. 
[52] reported a survey-based, case-control study of 
10,000 subjects aged 15 years or more of which 356 
cases were identified to have psoriasis. Of these, 71 
(19.9%) received treatment for hypercholestrolemia 
(37 had statins and 32 other drugs). Their study con-
firmed the association of overweight, smoking habits 
and beta-blocker intake with psoriasis and reported a 
decreased risk of psoriasis associated with statin in-
take. Other drugs with potential benefits may include 
thiazolidindiones (TZD) family that has positive ef-




Shafiq et al. [53] studied the effect of rosiglitazone, a 
commercially available TZD in psoriasis. In 70 pa-
tients with moderate to severe disease, the PASI 
scores improved significantly in treated vs. placebo 
patients with greater benefit being noted in those re-
ceiving higher doses of pioglitazone. No serious ad-
verse effects were noted. Psoriasis cleared or almost 
cleared in 40% of treated patients compared to 12.5% 
of patients receiving placebo. It was suggested that 
two-thirds of patients with plaque psoriasis will im-
prove with pioglitazone therapy.  
Traditional systemic therapies for psoriasis us-
ing methotrexate and cyclosporine may reduce the 
risk of cardiovascular disease by decreasing inflam-
mation however these treatments are limited by the 
potential for adverse effects such as hypertension, 
dyslipidemia, hyperhomocysteinemia, and renal and 
hepatic toxicity. Thus preventive measures may be 
required during therapy. Targeted biological thera-
pies with efalizumab, a humanized monoclonal IgG1 
antibody against CD11a, the a-subunit of leukocyte 
function-associated antigen 1 (LFA-1) [54, 55]  and 
infliximab, a TNF-α  blocking  agents [56, 57] have 
provided a major advance in the  treatment of the 
disease. Using these agents an integrated approach 
targeting at inflammation underlying both psoriasis 
and atherosclerosis may be useful in reducing cardi-
ovascular risk in patients with psoriasis. 
Conclusion 
In conclusion, considering the common me-
chanisms underlying the development of psoriasis 
and atherosclerosis, it is reasonable to postulate that 
early therapeutic strategies targeting such shared 
mechanisms would have considerable effects on both 
conditions. To this end, pharmaceutical drugs that 
both reduce hyperlipidemia and suppress inflamma-
tion such as statins could provide important candi-
dates for further clinical studies. It is intriguing to 
determine whether treatment of hyperlipidemia asso-
ciated with psoriasis would result in clinical im-
provement in psoriasis or alternatively treatment of 
psoriasis could improve cardiovascular disease. In-
deed, several studies reported that treatment of pso-
riasis contributes to the reduction of some risk factors 
of cardiovasculsr disease such as oxidative stress and 
inflammation, which may diminish the probability of 
cardiovascular events. However, an atherogenic pro-
file, at least an atherogenic lipidic profile and a resi-
dual inflammation seems to persist after treatment of 
psoriasis as reported in few studies. Taken together, it 
is important not only to be aware of the associations 
between psoriasis and other cardiovascular risk fac-
tors besides hyperlipidemia, but also to be able to 
identify all potentially treatable conditions which 
seem to favor the response to therapy in psoriasis 
patients, contributing to a better clearing of the le-
sions. 
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